Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Por Spiegel, Jay Y., McNamara, Caroline, Kennedy, James A., Panzarella, Tony, Arruda, Andrea, Stockley, Tracy, Sukhai, Mahadeo, Thomas, Mariam, Bartoszko, Justyna, Ho, Jenny, Siddiq, Nancy, Maze, Dawn, Schimmer, Aaron, Schuh, Andre, Sibai, Hassan, Yee, Karen, Claudio, Jamie, Devlin, Rebecca, Minden, Mark D., Kamel-Reid, Suzanne, Gupta, Vikas
Publicado no Blood Adv (2017)